Uses of interleukin-2
AssigneeSloan-Kettering Institute for Cancer Research
InventorsRoland Mertelsmann, Karl Welte, Salvatore Venuta
Life of this patent
Estimating the term…
Abstract
Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lympho This invention was made with support in part under Grants CA 08748, CA 22507, CA 25608, CA 20194, CA 21525, CA31525, PO1-CA-20194, AI 18 321-01, CA 23766 and CA 33050 awarded by the National Cancer Institute, National Institute of Health, DHEW. The government has certain rights in this invention.
Claims21
A method of normalizing a subject's immune response which comprises administering to the subject an amount of a human interleukin-2 effective to increase the proliferation of T cells and thus normalize the subject's immune response.
A method of treating a subject having an interleukin-2 dependent neoplasia which comprises administering to the subject an amount of a human interleukin-2 in combination with cytotoxin effective to inhibit growth of, or cause regression of, the neoplasia.
A method of treating a subject having an overreactive immunity which comprises administering to the subject an amount of a human interleukin-2 effective to decrease the reactivity of the subject's immune system.
A method of selectively eliminating interleukin-2 receptor-bearing cells from a subject which comprises administering to the subject an amount of a human interleukin-2 in combination with cytotoxin effective to selectively eliminate the interleukin-2 receptor-bearing cells.
Dependencies are inferred from the claim text.